ARWR Slides 17% as Shorts Build and the Street Holds Its Ground
Arrowhead Pharmaceuticals enters the week in an uncomfortable position — the stock has shed 17% in five sessions while short sellers quietly rebuild positions, even as a freshly initiated Citigroup Buy rating anchors…